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Abstract: Bacterial inclusion bodies (IBs) are protein-based nanoparticles of a few hundred 
nanometers formed during recombinant protein production processes in different bacterial hosts. 
IBs contain active protein in a mechanically stable nanostructured format that has been broadly 
characterized, showing promising potential in different fields such as tissue engineering, protein 
replacement therapies, cancer, and biotechnology. For immunomodulatory purposes, however, the 
interference of the format immunogenic properties—intrinsic to IBs—with the specific effects of the 
therapeutic protein is still an uncovered gap. For that, active and inactive forms of the catalytic 
domain of a matrix metalloproteinase-9 (MMP-9 and mutMMP-9, respectively) have been produced 
as IBs and compared with the soluble form for dermal inflammatory effects in mmp9 knock-out 
mice. After protein injections in air-pouches in the mouse model, MMP-9 IBs induce local neutrophil 
recruitment and increase pro-inflammatory chemokine levels, lasting for at least two days, whereas 
the effects triggered by the soluble MMP-9 format fade out after 3 h. Interestingly, the IB intrinsic 
effects (mutMMP-9 IBs) do not last more than 24 h. Therefore, it may be concluded that IBs could 
be used for the delivery of therapeutic proteins, such as immunomodulating proteins while 
preserving their stability in the specific tissue and without triggering important unspecific 
inflammatory responses due to the protein format. 
Keywords: inclusion body; matrix metalloproteinase-9; mmp9 knock-out mice; functional 
nanoparticle; immunogenicity 
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1. Introduction 
Recombinant proteins are used for a plethora of therapeutic applications, including cancer 
therapy, treatment of metabolic disorders, hormone substitution, infectious diseases, thrombolysis, 
and reproductive disorders, among others [1–5]. During recombinant protein production, bacterial 
host cells split the overproduced heterologous proteins into soluble and insoluble fractions. The 
insoluble fraction is also known as inclusion bodies (IBs), which are biophysically described as 
protein nanomaterials with sizes ranging from 50 to 800 nm, and are easily formed during 
recombinant protein production [6–8]. During many years IBs have been considered a waste product 
[9]. However, it has been gradually appreciated that IBs may be a promising alternative protein 
format per se [6,10,11]. Their structure and composition have been extensively characterized 
evidencing that proteins forming this rough nanomaterial [12,13] are biologically active [6,7,9]. It has 
also been documented that IBs are mechanically stable nanoparticles with slow protein-release 
properties, easily produced and isolated through economically affordable processes. It has been 
reported that they show even higher stability than other protein delivery strategies based on 
nanoparticles and they also have a better performance in vivo [14]. As a result of IB intrinsic 
properties, lacking in the soluble and other nanoparticulated formats [14], the applicability of IBs in 
biotechnology, material sciences, and medical purposes has been explored by different groups [6,10]. 
The nature of IBs, which combines biological activity and rough surfaces [12,15], allows one to 
successfully apply these as functional nanoparticles for tissue engineering purposes [16,17]. Another 
explored application is the injection of targeted-IBs for cancer therapy, proving that these 
nanoparticles are a stable source of releasing functional proteins [5,18,19]. Besides, it has been shown 
that IBs can perform an active role as adjuvants for vaccination purposes [20,21], but the real influence 
of the nanocluster format on inflammatory effects of IBs and their influence on immune-related 
therapies have never been assessed. Therefore, the exploration of protein-based nanoparticles as a 
new promising therapeutic format has still some uncovered gaps. 
To determine the potential of IBs to deliver an immune-related therapeutic protein in vivo, and 
to elucidate the possible side-effects of the format on the local inflammatory response, matrix 
metalloproteinase-9 (MMP-9, also known as gelatinase B) was used as a model protein. MMP-9 is an 
enzyme that has a relevant role in many biological processes such as wound healing, angiogenesis, 
reproduction, growth, and tissue development [22] and could be a very relevant drug in the context 
of several diseases. It is mainly secreted by neutrophils by degranulation and induced in endothelial 
cells and it is involved in the degradation and remodeling of the extracellular matrix and in 
chemotaxis [23]. Considering the relevance of MMP-9, we have used a catalytically active fragment 
of bovine MMP-9 and an inactive mutant of this enzyme produced in Lactococcus lactis as IBs [15,24], 
and we have tested these in a mouse model of skin inflammation. This study demonstrates that the 
IB format has only a limited inflammatory effect without interference with the specific activity of the 
model molecule embedded in the protein nanomaterial. 
2. Materials and Methods 
2.1. Bacteria Strains and Plasmids 
Lactococcus lactis subsp. cremoris NZ9000 double mutant EmR ClpP− HtrA− provided by INRA 
(Jouy-en-Josas, France; patent n. EP1141337B1) was used in this study. A bovine MMP-9 fragment 
from Phe107 to Pro449 (NCBI, NM_174744.2), which comprises the catalytic, the fibronectin and the 
zinc-binding domains, was cloned into the plasmid CmR pNZ8148 (MoBiTech GmbH, Göttingen, 
Germany) and transformed into competent L. lactis ClpP−HtrA− as described in Cano-Garrido et al. 
[15]. A similar MMP-9 cDNA fragment with a single amino acid substitution (E402Q) [25,26], which 
encodes a proteolytic inactive form of MMP-9 (named mutMMP-9 from now on), was cloned into the 
pNZ8148 plasmid and transformed into competent L. lactis ClpP−HtrA−. Both genes were C-
terminally fused to a His-tag and were codon-optimized for L. lactis (Thermo Fisher Scientific, 
GeneArt GmbH, Regensburg, Germany) [15]. A scheme of the recombinant MMP-9 structure and 
functionality is provided in Figure 1a. 
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Figure 1. Recombinant MMP-9 and mutMMP-9 structures and functionality. (a) Recombinant bovine 
MMP-9. On top, domain (dn.) structure of the complete bovine MMP-9 compared with the 
recombinantly expressed protein fragment (Phe107–Pro449) and its proteolytic inactive mutant [25]. 
At the bottom, 3D model for P52176 (Phe107 to Gly444) with the mutated residue E402Q superposed 
(WT: Glutamic (E) colored in orange, mutant: Glutamine (Q) in purple). Left panel: full view of the 
generated models. Right panel: detail of the region with the mutated residue that impairs 
functionality in the mutMMP-9. (b) SEM (left) and TEM (middle and right) images of the MMP-9 IBs 
obtained from L. lactis. Recombinant MMP-9 and mutMMP-9 structures and functionality. (c) 
Degradation kinetics for MMP-9 IBs (black), MutMMP-9 IBs (grey), and the soluble MMP-9 (blue) 
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(left) and the corresponding specific activity (SA) for the IBs (right). The soluble MMP-9 SA was 
2,282.8 ± 21.9 rfu/min/µg. Error bars indicate standard errors (n = 3). (d) Zymography analysis 
showing that MMP-9 degrades gelatin in an electrophoresis gel. st. Standard MMP-9 mixture as the 
marker (see section 2.8 for details); mut. IBs. Mutant MMP-9 IBs; act. IBs. Active MMP-9 IBs; sol. 
Soluble MMP-9; kDa. kiloDalton. (e) Recombinant MMP-9 yields either for soluble and IB forms; * 
Yield for peak 1 in the chromatography of the solubilized MMP-9; total soluble MMP-9 yield was 4.89 
± 2.8 mg/L of culture. 
2.2. MMP-9 Modelling 
Protein structure homology models for a Bos taurus MMP-9 selected region (from F107 to G444) 
were built with UCSF Modeller 9v13 [27] for wild type (WT) (Uniprot code P52176) and mutant 
E402Q proteoforms, using the Crystal structure of human MMP-9 (PDB code 1L6J, chain A [28] 
residues from G105 to G444) as a template. Models were selected according to the best DOPE score 
[29]. Structure superposition was carried out with ProFit [30], using only the main chain atoms 
(N,CA,C,O).  
2.3. MMP-9 and mutMMP-9 IBs Production in L. lactis 
Bacteria were grown without shaking at 30 °C in M17 broth supplemented with glucose (0.5%). 
Antibiotics were added for plasmid maintenance—chloramphenicol (5 µg/mL) and erythromycin (2.5 
µg/mL). Re-inoculated cultures were induced with nisin (12.5 ng/mL) to produce MMP-9 or 
mutMMP-9 at an OD600 of 0.4–0.6, and productions were performed along 3 h. Cultures were 
recovered and centrifuged at 6,000× g for 30 min at 4 °C. 
2.4. MMP-9 and mutMMP-9 IBs Purification 
After recombinant protein expression and recovery of bacteria, each pellet (50 mL) was 
suspended in sterile PBS (30 mL) and frozen overnight (O/N) at −80 °C. With the following procedure 
we aimed at the disruption of all bacteria by several freeze-thaw (F/T) cycles and mechanical and 
chemical procedures. Briefly, thawed bacteria were subjected to 3 rounds of French Press (Thermo 
FA-078A) at 1,500 psi in the presence of protease inhibitors (Complete EDTA-free, Roche). After a 
new F/T, samples were incubated for 2 h with lysozyme (0.01 mg/mL) at 37 °C and rotary shaking at 
250 rpm. After another F/T cycle, the lysate was incubated for 1 h with Triton X-100 (4 µg/mL) at RT 
in an orbital rotator shaker. An aliquot of the lysate was plated on agar-M17 broth with glucose (0.5%) 
and incubated O/N at 30 °C as a first sterility control. Additional F/T cycles were performed until no 
bacterial colonies were grown on the plates. Next, the lysates were incubated with NP-40 (0.25 µL 
per mL of sample, 0.25 µL/mL) for 1 h at 4 °C in orbital shaking, followed by 1 h with MgSO4 (0.6 
µL/mL, stock 1 M) and DNAse I (0.6 µL/mL, stock 1 mg/mL) at 37 °C and 250 rpm. Lysates were 
centrifuged at 6,000× g for 30 min at 4 °C. Each pellet was suspended in lysis buffer (5 mL) with Triton 
X-100 (0.5%) and F/T. Samples were centrifuged, and under sterile conditions, the supernatant was 
discarded and pellets were suspended in sterile GIBCO® Dulbecco's Phosphate-Buffered Saline 
(DPBS; Gaithersburg, MD, USA) (5 mL). The resulting lysate was aliquoted and centrifuged at 20,000× 
g for 15 min, and the protein pellets were frozen at −80 °C. Some aliquots were diluted in eukaryotic 
culture media, transferred into the wells of a 96-well plate, and incubated for 48 h at 37 °C and CO2 
(5%) as a final sterility control.  
2.5. Purification of Soluble MMP-9 
The soluble MMP-9 fraction and IBs were obtained as described in the work of Gifre-Renom et 
al. [24]. Briefly, cultures were recovered after 3 h of production and were centrifuged at 6,000× g for 
15 min at 4 °C. Each pellet from 500 mL cultures was suspended in PBS (30 mL) with protease 
inhibitors and subjected to 4 rounds of French Press at 1500 psi. Thereafter, lysates were incubated 
with lysozyme (0.05 mg/mL) for 2 h at 37 °C and 250 rpm orbital shaking. Pellets were obtained by 
centrifuging the lysates at 15,000× g for 45 min at 4 °C and were washed in mQ-H2O. After 15 min 
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centrifugation, pellets were weighed and resuspended in solubilization buffer (40 mL/g) containing 
Tris (40 mM, pH = 8) and N-Lauroyl sarcosine (0.2%). The solution was covered with parafilm and 
incubated on a magnetic stirrer O/N at 4 °C. The obtained solution was centrifuged for 20 min at 
20,000× g and at 4 °C and the supernatant was collected, filtered, and further purified through 
Immobilized Metal Affinity Chromatography (IMAC). One mL HiTrap Chelating columns (GE 
Healthcare, Chicago, IL, USA) were used in an ÄKTA purifier FPLC system (GE Healthcare, Chicago, 
IL, USA), and both the binding and the elution buffer contained N-Lauroyl sarcosine (0.2%). The 
MMP-9 was eluted by gradually increasing the imidazole concentration until 500 mM, and holding 
the gradient at each peak to allow peak separation (data not shown). The eluted peaks were dialyzed 
O/N to PBS at 4 °C with gentle agitation and centrifuged at 15,000× g for 15 min at 4 °C to remove 
possible precipitated protein. The supernatants were filtered under sterile conditions, aliquoted and 
stored at −80 °C until use. 
2.6. Protein Determination by Western Blot and Coomassie Blue Staining Analyses 
The MMP-9 IBs and mutMMP-9 IBs were quantified by Western blot analysis (ImageJ NIH, 
version 1.46r, U. S. National Institutes of Health, Bethesda, MD, USA) using a soluble MMP-9 
standard. The soluble MMP-9 peaks were quantified by Nanodrop (Thermo Scientific, Waltham, MA, 
USA) indicating the MMP-9 parameters (MW: 39 kDa and ε: 70,080 M−1 cm−1; ProtParam-ExPASy, 
https://web.expasy.org/protparam/). The purity of MMP-9 IBs, mutMMP-9 IBs, and the soluble 
MMP-9 were analyzed by Coomassie blue staining.  
2.7. MMP-9 Activity Determination in Vitro by DQgelatinTM Assay 
MMP-9 IBs (10 µg), mutMMP-9 IBs (10 µg), or soluble MMP-9 (10 µg) were plated in a 
transparent flat-bottom black 96-well plate in triplicate, at a final volume of 150 L in assay buffer 
containing CaCl2 (5 mM), Tris (50 mM, pH 7.6), NaCl (150 mM), and Tween20 (0.01%). Immediately 
after adding dye-quenched gelatin (DQgelatinTM, Invitrogen, Carlsbad, CA, USA) (0.25 µg per well), 
the plate was bottom-read every three minutes, O/N, in a fluorescence microplate reader (Victor III 
multilabel counter, Perkin-Elmer, Waltham, MA, USA) at 495/515 nm (excitation/emission 
wavelengths). The specific activity of MMP-9 was extracted for each sample from the kinetics data, 
by obtaining the initial velocity (relative fluorescence units per minute, rfu/min) for each g of MMP-
9 in the wells (rfu/min/µg). 
2.8. MMP-9 Proteoform Determination in vitro by Gelatin Zymography Analysis 
MMP-9 IBs (7 g), mutMMP-9 IBs (7 g), and soluble MMP-9 (0.6 ng) were loaded in non-
denaturing conditions in SDS-PAGE (10%) gels with gelatin (1%). A standard mix of MMP-9 was 
loaded as a ladder, containing a multimeric (approximately 250 kDa), a monomeric (92 kDa), and a 
truncated (46 kDa) form of human MMP-9 [31,32]. After electrophoresis, gels were washed and 
incubated O/N with developing buffer at 37 °C and were further stained with Coomassie blue in 
acetic acid (20%), followed by distaining incubations with strong and soft methanol-acetic acid 
solutions [32]. 
2.9. MMP-9 Injection in Mouse Air-Pouches 
A total of sixty C57BL/6 MMP-9 KO mice [33], males and females, were injected intra-dermally 
on the back with filtered air (3 mL, 0.2 µm filter) on days 0 and 3 to establish the air-pouch 
compartment, following the standardizations described in the work of Vandooren et al. [34]. Protein 
samples or DPBS (200 µL) were injected at day 6. Protein injections consisted of MMP-9 (40 µg, 
soluble or IBs) or mutMMP-9 (40 µg, IBs) in DPBS (200 µL) per injection. The soluble MMP-9 
corresponded to the most active fraction (by DQgelatinTM assay) among the different peaks obtained 
in the chromatography profile (data not shown). At time intervals of 3, 24, and 48 h after injections, 
mice were euthanized with an intraperitoneal injection of pentobarbital (Dolethal) solution (40 
mg/Kg). The exudates in the air-pouches were collected by injecting PBS (2 mL) with heparin (20 
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U/mL) followed by a gentle massage on the air-pouch and the recovery of all the content. Without 
taking off the needle, the process was repeated with additional PBS (3 mL) and the total volume was 
cooled on ice. All experimental procedures were approved by the institutional Ethics Committee (KU 
Leuven) under license LA1210243 for animal welfare (Project 277/2014, 01-01-2016). 
2.10. Exudate Cell Count Analysis 
The collected exudate volumes were centrifuged at 300× g for 5 min in a swing-out cytocentrifuge 
and supernatants were preserved at −80 °C for cytokine analysis. Cell pellets were washed in ACK 
buffer (1 mL, GIBCO®, Life Technologies) to lyse erythrocytes. After centrifugation, cells were 
resuspended in PBS and were counted in a Neubauer chamber after trypan blue staining to exclude 
dead cells. 
2.11. Flow Cytometry Analysis 
Immediately after viable cell counting, we incubated the cells (5 to 10 × 105 cells) in Fc-receptor-
blocking antibodies and ZombieAqua-BV510 at RT for 20 min. A master-mix was prepared with the 
selected antibodies for the characterization of different cell populations: CD11b-APC (monocytes 
neutrophils, eosinophils, and dendritic cells), CD11c-BV711 (dendritic cells), Ly6C-FITC (monocytes, 
macrophages and neutrophils) and Ly6G-PE (neutrophils and eosinophils). All the antibodies were 
purchased from eBioscience (Thermo Fisher Scientific). Cells were incubated with the master-mix (10 
µL) for 30–45 min at 4 °C protected from light and were washed twice in PBS. Cells were fixed in 
formaldehyde (0.37%) and acquired in a fluorescence-activated cell sorting (FACS) Fortessa flow 
cytometer (BD Biosciences, San Jose, CA, USA). Data were analyzed with the BD FACSDiva™ 
software v6.1.3. 
After compensating the signals for each fluorochrome, live cells excluding doublets were 
selected. Briefly, cell debris were excluded gating FSC-Amid-pos SSC-Amid-pos quadrant in a dot plot. 
From this population, singlets were selected drawing a diagonal gate in an FSC-A vs. FSC-H plot 
excluding outlier events (doublet cells). Afterward, from the last gate obtained, live cells were gated 
in a new plot selecting the ZombieAqua-BV510-Aneg cell population. From these cells, the CD11b-
APC-Apos population plotted vs. Ly6C-FITC-A was gated, and this gate was defined as monocytes, 
macrophages, and neutrophils together (MMN, from now on). From live cell gate, neutrophils were 
selected gating the Ly6G-PE-Apos CD11b-APC-Apos population, and dendritic cells were selected 
gating the CD11c-BV711-Apos CD11b-APC-Aneg population. Macrophages were selected as the Ly6C-
FITC-Apos Ly6G-PE-Aneg population. Finally, monocytes were defined as the difference between 
MMN population and the gates in isolated plots for neutrophils and macrophages. All gates were 
quantified as a percentage of events from total live cells. 
2.12. Chemokine ELISA Analysis 
The presence of chemokines in the exudate supernatants from the air-pouch assay were 
analyzed by ELISA (DuoSet ELISA, from R&D Systems, Minneapolis, MN, USA). The chemokines 
studied correspond grossly to the recruitment of neutrophils (CXCL1/Gro-α/KC and CXCL2/Gro-
β/MIP-2α), monocytes and dendritic cells (CCL2/MCP-1), and macrophages (CCL3/MIP-1α). The 
protocol followed was in accordance with the guidelines provided by the manufacturer, and all 
washing steps were done twice in PBS containing Tween20 (0.05%). Briefly, flat-bottom 96-well plates 
were coated with the pertinent capture antibody O/N at 4 °C and washed. Plates were blocked with 
BSA (0.5%) containing Tween20 (0.05%) for 1 h at RT and washed again. Diluted samples were plated 
in duplicate and incubated O/N at 4 °C and plates were washed. Plates were incubated for 2 h at RT 
with the provided biotinylated detection antibodies. After washing, the streptavidin-HRP detection 
solution was added and incubated for 20 min at 37 °C protected from light. Plates were washed and 
incubated for 20 min with substrate solution at RT and protected from light, and the reaction was 
stopped with stop solution provided in the kit. Reads were done in a plate reader at 450 nm and the 
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blank was subtracted from all wells. A sigmoidal standard curve equation and its R2 were obtained 
using the commercial standards provided in each kit. 
2.13. Statistical Analysis 
The animal experiments were performed three times with three mice per condition. Because the 
experimental variability was limited, data from 3 to 6 animals per condition were pooled. Statistics 
were carried out with a total of sixty mice. Twelve exudates were obtained after 3 h of protein 
injection, 24 exudates were collected after 24 h, and 24 exudates after 48 h. Variables were 
transformed to normalize data when necessary. Data were analyzed using a fixed-effect model (JMP, 
SAS Institute Inc., Cary, NC, USA). The model included treatment and time and its interaction as 
main effects, the experiments, and the laboratories where the cytometry data were analyzed as a 
random effect. Animals were not considered as the random effect as no repeated measures were 
performed on the same animal. Means and standard deviations represented in graphs correspond to 
non-transformed data, while p-values and asterisks correspond to the Tukey test analyses using 
transformed data when required. Asterisks depict significant differences to the control group (DPBS). 
Detailed differences between treatments and time points represented by different letters can be found 
in the Supplementary material (Tables S1, S2, and S3). 
3. Results 
Based on structural and functional data, we have produced both active and inactive (or mutant) 
forms of MMP-9 IBs (MMP-9 IBs [15] and mutMMP-9 IBs, respectively) to evaluate the potential of 
IBs as a therapeutic and immunomodulatory protein biomaterial. Although both have an almost 
identical structure [25,26], the substitution of the essential glutamic acid in the Zn2+ binding domain 
for glutamine (E402Q) (Figure 1a) has generated a catalytically inactive MMP-9 variant (mutMMP-
9). Soluble MMP-9, MMP-9 IBs, and mutMMP-9 IBs were produced in Lactococcus lactis and purified 
as detailed in Figure S1 [15,24]. The biophysical properties of the IBs format are illustrated in Figure 
1b: these consisted of electron-dense nanoparticles that clustered in the host cells. The three MMP-9 
recombinant forms (soluble MMP-9, MMP-9 IBs, and mutMMP-9 IBs) were compared for catalysis. 
As expected, soluble MMP-9 presented higher gelatinolytic activity than MMP-9 in IBs and the 
mutMMP-9 IBs did not show activity (Figure 1c). These results were corroborated by gelatin 
zymography analysis (Figure 1d). 
To test the inflammatory capability of the different MMP-9 forms (soluble MMP-9, MMP-9 IBs, 
and mutMMP-9 IBs), these were injected into air-pouches from mmp9 knock-out mice, and exudates 
were recovered at 3, 24, and 48 h to analyze the recruitment of myeloid cells; DPBS was used as the 
negative control. At 3 h post-injections, no significant differences in total cell counts were observed 
for any of the MMP-9 treatments (Figure 2a). However, cell recruitment at 24 h was significantly 
higher in the animals injected with IBs, while soluble MMP-9 treatment did not differ from the control 
(Figure 2a). Interestingly, after 48 h, the cells recruited in the air-pouches remained high in mice 
injected with MMP-9 IBs while in mice treated with mutMMP-9 IBs total cell count values returned 
to basal levels (Figure 2a). 
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Figure 2. Cellular component analyses in the recovered exudates of the air pouches. (a) Total cell 
counts at 3, 24, and 48 h after injections with the four different treatments. Means and SEM (error 
bars) from non-transformed data are represented. Asterisks depict significant differences (p < 0.005). 
Detailed differences between treatments and time points represented by different letters can be found 
in Table S1 in the Supplementary material. (b) Relative quantification of the different immune cell 
populations analyzed by flow cytometry. Means and SEM (error bars) from non-transformed data are 
represented. Asterisks depict significant differences (p < 0.0001). Detailed differences between 
treatments and time points represented by different letters can be found in Table S2 in the 
Supplementary material. 
To determine the differences in recruited inflammatory cells, we quantified different cell 
populations (neutrophils, macrophages, monocytes, and dendritic cells) by flow cytometry (Figure 
2b). At 3 h post-injection, all MMP-9-based treatments showed a significant increase in neutrophil 
percentages compared to DPBS injections (Figure 2b). At longer times (24 and 48 h), only the animals 
injected with IBs kept neutrophil levels above those injected with DPBS buffer. Both MMP-9 IBs and 
mutMMP-9 IBs injections increased neutrophil recruitment after 24 h, whereas after 48 h the 
granulocyte influx was only observed in the MMP-9 IBs treated pouches (Figure 2b). Macrophages, 
monocytes, and dendritic cells evolved differently from neutrophils, but all three cell populations 
came with similar profiles (Figure 2b). At 3 h after injections, and for all MMP-9 treatments, a decrease 
in macrophages, monocytes, and dendritic cells was observed compared to DPBS treatment. No 
differences were observed for mutMMP-9 IBs treated animals at 24 h and 48 h (Figure 2b). By contrast, 
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exudates from animals treated with active MMP-9 IBs showed a decrease not only in macrophages 
but also in monocytes and dendritic cells (Figure 2b) after all the time intervals. 
To better evaluate whether cell recruitment was a direct effect of the protein biomaterial or an 
indirect effect through induction of host-derived chemokines for the detected leukocytes, we studied 
major neutrophil and mononuclear cell chemokines. Supernatants from air-pouch exudates were 
analyzed to determine the levels of CXCL1 and CXCL2 (chemokines that recruit neutrophils), CCL2 
(chemokines for monocytes and dendritic cells) and CCL3 (chemokines for macrophages) (Figure 3).  
 
Figure 3. Pro-inflammatory chemokine concentrations in the recovered supernatants of the air 
pouches. (a) CXCL1; (b) CXCL2; (c) CCL2; (d) CCL3. Means and SEM (error bars) from non-
transformed data are represented. Asterisks depict significant differences (p < 0.0001 in a, b, and c, 
and p < 0.005 in d). Detailed differences between treatments and time points represented by different 
letters can be found in Table S3 in the Supplementary material. 
At 3 h after injections, both MMP-9 IBs and mutMMP-9 IBs treatments significantly increased 
CXCL1 levels in comparison with the control and the soluble MMP-9 treated exudates (Figure 3a). In 
addition, mice treated with MMP-9 IBs showed a 2-fold increase in CXCL1 levels in the air pouch 
exudates in comparison with those of mice treated with mutMMP-9 IBs (Figure 3a). After 24 and 48 
h, no differences were observed for CXCL1 in any of the conditions studied. MMP-9 IBs and the 
mutMMP-9 IBs had an impact on the levels of CXCL2 at 3 h (Figure 3b), whereas at later time points 
(24 and 48 h) only the MMP-9 IBs treatment increased CXCL2 levels above the negative control and 
soluble MMP-9, corroborating the different behavior of MMP-9 IBs compared to mutMMP-9 IBs 
(Figure 3b). CCL2 profiles showed only increases at 3 h for both MMP-9 IB- and mutMMP-9 IB-based 
treatments, which decreased after 24 h (Figure 3c). Similarly, CCL3 levels increased in pouches 
treated with MMP-9 IBs and mutMMP-9 IBs at 3 h in comparison with control and soluble MMP-9 
(Figure 3d). After 24 h of injections, only MMP-9 IBs maintained significantly high levels of CCL3 
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compared to DPBS, while the CCL3 levels after the soluble MMP-9 treatment tended to be greater 
than those after DPBS injections (Figure 3d).  
4. Discussion 
Although high purities can be achieved for IBs, meaning that the main content in these particles 
is the recombinant protein of interest, other impurities such as lipids, RNA and DNA, and other 
proteins, can be trapped in IBs and are co-purified along with the protein of interest [10]. It has been 
previously reported that IBs display intrinsic immunostimulant properties that allow these to be used 
as adjuvants [20]. IBs composed of immunostimulant proteins, such as cytokines, have been reported 
to provide zebrafish with a greater protective performance in vivo [21]. However, the interference of 
the intrinsic properties of IBs with the immune performance of IBs has never been elucidated before, 
and this may be critical when assessing the therapeutic potential for immunostimulant protein-based 
IBs. For that, in this study, MMP-9 has been chosen as an immunostimulant protein model to address 
the inflammatory effects in MMP-9-based IBs produced in an LPS-free recombinant system (L. lactis). 
MMP-9 IBs used in this study have been deeply characterized by a physicochemical perspective in a 
previous study [15], but in vivo behavior in terms of the immune response has not been reported 
before. Besides chemokines, after tissue damage or a threatening presence, neutrophils, and other 
leukocytes and endothelial cells secrete MMP-9 as a proenzyme, and this is activated chemically by 
neutrophil products and proteolytically in the extracellular matrix (ECM) due to the cleavage of the 
pro-peptide. Then, MMP-9 can degrade ECM components and cell adhesion molecules, increasing 
the endothelial permeability and facilitating the transmigration of neutrophils and other immune 
cells to places of tissue damage and promoting an inflammatory response [23]. In this study, we have 
used a recombinant form of MMP-9 lacking the pro-peptide (Figure 1a) [15], being this immediately 
able to start the catalysis of ECM components. This MMP-9 form lacks the hemopexin domain that 
reinforces the binding of tissue inhibitors of metalloproteinases-1 and -3 (TIMP-1, -3) to the enzyme 
[31,35], making it even more effective in their function in vivo.  
The air-pouch model in mice provides a tool to determine how a foreign substance or 
formulation thereof influences inflammatory reactions in vivo [34]. Thus, purified IBs (Figure 1b) of 
MMP-9 and mutMMP-9 (catalytically active and inactive, respectively; Figure 1c,d) were 
administered into air pouches of a mouse model of skin inflammation [34], and soluble MMP-9 was 
used as a positive control. By using mmp9 knock-out mice for this application [33], we aimed to avoid 
artifacts caused by endogenous mouse MMP-9. At 3 h after the injections into air pouches, all the 
MMP-9-based treatments (soluble MMP-9, MMP-9 IBs, and mutMMP-9 IBs) showed a significant 
increase in neutrophil percentages (Figure 2b), in agreement with being the first cell type arriving 
after a challenge or tissue damage [36]. This indicated a fast effect of MMP-9 in the soluble format, 
and an inflammatory effect of the IB nanocluster format. With these data, we could not claim that 
MMP-9 activity in IBs is essential, since no significant differences were observed between MMP-9 IBs 
and mutMMP-9 IBs (Figure 2b). However, at 24 h, the cellular levels for the pouches treated with the 
soluble MMP-9 returned to the levels of DPBS treated mice (Figure 2b, excluding macrophages), 
whereas in mice treated with active MMP-9 IBs the modulation of all the analyzed cell populations 
remained different. In accordance with a previous article [14], this indicated that the soluble MMP-9 
format seems more labile than the MMP-9-based nanoparticles (IBs), for which unspecific effects 
(carried out by mutMMP-9 IBs) start to disappear yet at 24 h (Figure 2b, except for neutrophils) and 
are inexistent at 48 h. 
Interestingly, there was a strong correlation between early chemokine levels—CXCL1, CXCL2, 
CCL2, and CCL3—and myeloid cell recruitment (Figures 2 and 3). Firstly, both IBs formats—active 
and inactive MMP-9 IBs—increased all the analyzed chemokine levels at 3 h while soluble MMP-9 
did not (Figure 3). This effect was consistent with the increase in cell recruitment—mainly 
neutrophils—at 24 h for these treatments (Figure 2b). Secondly, at 24 and 48 h, only in pouches treated 
with active MMP-9 IBs, an increase in CXCL2 and CCL3 levels was reported (Figure 3b,d), coinciding 
with the increase in neutrophils at 48 h exclusively for the active MMP-9 IBs treatment (Figure 2b).  
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These results are relevant because they elucidated that the recombinant MMP-9 produced in L. 
lactis as IBs [15,24] triggers an inflammatory response due to its degradative capability and not 
because of the inflammatory response to the nanomaterial (IBs) itself. Thus, while the response 
triggered by the soluble MMP-9 disappeared after 24 h, the injection of a similar amount of MMP-9 
in the IB format extended its effects for more than 48 h, confirming that the IB format provided 
stability to active MMP-9 [14,37]. Hence, IBs have the potential to be considered in applications such 
as cancer therapy [5,18,19], vaccination and infectious diseases [4], among others, since the nature of 
the IB format only transiently stimulates a local and short inflammatory response. 
5. Conclusions 
We report here that the IB format has only a limited inflammatory effect without interference 
with the specific activity of the model molecule in the protein nanoparticles. In addition, we have 
shown that the recombinant protein embedded in IBs results in more sustained in vivo effects 
compared to the soluble (and standard) form. Although more examples will be needed, our work 
exemplifies the potential of this protein-based nanomaterial as a new and promising delivery tool. 
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